ImmuCell Corporation
ICCC
$6.25
$0.1652.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 28.27M | 27.30M | 26.49M | 23.84M | 23.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.27M | 27.30M | 26.49M | 23.84M | 23.22M |
| Cost of Revenue | 17.28M | 17.90M | 18.15M | 16.94M | 16.65M |
| Gross Profit | 10.99M | 9.41M | 8.35M | 6.89M | 6.58M |
| SG&A Expenses | 5.66M | 5.83M | 5.68M | 5.49M | 5.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.13M | 27.12M | 27.73M | 26.58M | 26.57M |
| Operating Income | 2.14M | 184.50K | -1.23M | -2.74M | -3.35M |
| Income Before Tax | 1.77M | -261.20K | -2.15M | -3.81M | -4.05M |
| Income Tax Expenses | 11.10K | 10.50K | 9.90K | 5.20K | 4.10K |
| Earnings from Continuing Operations | 1.76 | -0.27 | -2.16 | -3.81 | -4.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.76M | -271.70K | -2.16M | -3.81M | -4.05M |
| EBIT | 2.14M | 184.50K | -1.23M | -2.74M | -3.35M |
| EBITDA | 4.83M | 2.88M | 1.45M | -49.80K | -633.60K |
| EPS Basic | 0.19 | -0.06 | -0.28 | -0.49 | -0.52 |
| Normalized Basic EPS | 0.12 | -0.04 | -0.15 | -0.26 | -0.31 |
| EPS Diluted | 0.18 | -0.07 | -0.29 | -0.50 | -0.53 |
| Normalized Diluted EPS | 0.12 | -0.04 | -0.15 | -0.26 | -0.31 |
| Average Basic Shares Outstanding | 35.11M | 33.89M | 32.66M | 31.48M | 31.06M |
| Average Diluted Shares Outstanding | 35.11M | 33.89M | 32.66M | 31.48M | 31.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |